Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 12, 2020 - Issue
Submit an article Journal homepage
145
Views
5
CrossRef citations to date
0
Altmetric
Original Research

US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma

Jan Bassali1 Global Medical and Scientific Affairs Department, Karyopharm Therapeutics, Newton, MA, 02459, USACorrespondence[email protected]
View further author information
,
Ian Gopal Gould2 Research Health Economy, RTI Health Solutions, Research Triangle Park, NC27709-2194, USAView further author information
,
James A Kaye3 Epidemiology, RTI Health Solutions, Research Triangle Park, NC, USAORCID Iconhttps://orcid.org/0000-0002-9357-4227View further author information
ORCID Icon,
Deirdre Mladsi4 Health Economics - Strategy and Early Modeling, RTI Health Solutions, Research Triangle Park, NC, USAORCID Iconhttps://orcid.org/0000-0001-8113-1149View further author information
ORCID Icon &
Jyotsna Mehta5 HEOR, Karyopharm Therapeutics, Newton, MA02459, USAORCID Iconhttps://orcid.org/0000-0002-7624-6088View further author information
ORCID Icon
Pages 317-325 | Published online: 19 Jun 2020

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Anshul Shah, Jonathan C Tosh, Apoorva Ambavane, Andreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin, Boris Gorsh, Eric M Maiese & Feng Wang. (2021) Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. ClinicoEconomics and Outcomes Research 13, pages 789-800.
Read now
Mike Dolph, Gabriel Tremblay & Hoyee Leong. (2021) US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma. ClinicoEconomics and Outcomes Research 13, pages 493-502.
Read now
Kishan K. Patel, Terri Parker, Mengyang Di, Noffar Bar, Scott F. Huntington & Smith Giri. (2021) Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia & Lymphoma 62:11, pages 2777-2784.
Read now

Articles from other publishers (2)

Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach & Paul G. Richardson. (2023) Selinexor: Targeting a novel pathway in multiple myeloma. eJHaem.
Crossref
. (2020) Selinexor affordable in US for relapsed or refractory multiple myeloma. PharmacoEconomics & Outcomes News 857:1, pages 26-26.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.